Magazine Article | May 9, 2017

Where Others Have Failed, Genocea Sees Promise In T-Cell Vaccines

Source: Life Science Leader

By Mike Goodman, Contributing Writer

Genocea Biosciences is at the forefront of companies harnessing T-cell immunity to conquer the most difficult infectious diseases. Founded in 2006 with antigen discovery technology out of Harvard University, the Cambridge, MA-based company has spent the past decade progressing GEN-003, an HSV-2 (genital herpes) therapeutic vaccine, through the clinic and launching a personalized cancer vaccine franchise that will file its first IND (investigational new drug) this year and enter the clinic in 2018.